Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.

Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath Iii CA, Huh WK, Bevis KS, Kim KH, Straughn JM Jr, Gower BA.

J Nutr. 2018 Aug 1;148(8):1253-1260. doi: 10.1093/jn/nxy119.

PMID:
30137481
2.

Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.

Becker DA, Leath CA 3rd, Walters-Haygood CL, Smith BQ, Bevis KS.

Am J Clin Oncol. 2018 May 18. doi: 10.1097/COC.0000000000000468. [Epub ahead of print]

PMID:
29782365
3.

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.

PMID:
29523763
4.

Lay Patient Navigators' Perspectives of Barriers, Facilitators and Training Needs in Initiating Advance Care Planning Conversations With Older Patients With Cancer.

Niranjan SJ, Huang CS, Dionne-Odom JN, Halilova KI, Pisu M, Drentea P, Kvale EA, Bevis KS, Butler TW, Partridge EE, Rocque GB.

J Palliat Care. 2018 Apr;33(2):70-78. doi: 10.1177/0825859718757131. Epub 2018 Feb 12.

PMID:
29432705
5.

Values and worries of ovarian cancer patients.

Pisu M, Kenzik KM, Rim SH, Funkhouser EM, Bevis KS, Alvarez RD, Cantuaria G, Rocconi RP, Martin MY.

Gynecol Oncol. 2017 Nov;147(2):433-438. doi: 10.1016/j.ygyno.2017.08.028. Epub 2017 Sep 7.

6.

Implementation and Impact of Patient Lay Navigator-Led Advance Care Planning Conversations.

Rocque GB, Dionne-Odom JN, Sylvia Huang CH, Niranjan SJ, Williams CP, Jackson BE, Halilova KI, Kenzik KM, Bevis KS, Wallace AS, Lisovicz N, Taylor RA, Pisu M, Partridge EE, Butler TW, Briggs LA, Kvale EA; Patient Care Connect Group.

J Pain Symptom Manage. 2017 Apr;53(4):682-692. doi: 10.1016/j.jpainsymman.2016.11.012. Epub 2017 Jan 3.

PMID:
28062341
7.

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.

Thomas ED, Meza-Perez S, Bevis KS, Randall TD, Gillespie GY, Langford C, Alvarez RD.

J Ovarian Res. 2016 Oct 27;9(1):70.

8.

Patient-centered support in the survivorship care transition: Outcomes from the Patient-Owned Survivorship Care Plan Intervention.

Kvale EA, Huang CS, Meneses KM, Demark-Wahnefried W, Bae S, Azuero CB, Rocque GB, Bevis KS, Ritchie CS.

Cancer. 2016 Oct 15;122(20):3232-3242. doi: 10.1002/cncr.30136. Epub 2016 Jul 7.

9.

Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.

Becker DA, Thomas ED, Gilbert AL, Boone JD, Straughn JM Jr, Huh WK, Bevis KS, Leath CA 3rd, Alvarez RD.

Gynecol Oncol. 2016 Jul;142(1):25-29. doi: 10.1016/j.ygyno.2016.04.539. Epub 2016 May 10.

PMID:
27130405
10.

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK.

Gynecol Oncol. 2015 Dec;139(3):413-8. doi: 10.1016/j.ygyno.2015.06.041. Epub 2015 Jul 2.

PMID:
26144600
11.
12.

A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.

Previs RA, Bevis KS, Huh W, Tillmanns T, Perry L, Moore K, Chapman J, McClung C, Kiet T, Java J, Chan J, Secord AA.

Gynecol Oncol. 2014 Mar;132(3):531-6. doi: 10.1016/j.ygyno.2014.01.036. Epub 2014 Jan 25.

PMID:
24472410
13.

Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women.

Leath CA 3rd, Bevis KS, Numnum TM, Ramsey PS, Huh WK, Straughn JM Jr.

J Reprod Med. 2013 Jul-Aug;58(7-8):279-84.

PMID:
23947076
14.

Vulvar histoplasmosis as a rare cause of genital ulceration.

Shine MM, Shah MM, Hanna CA, Bevis KS.

Obstet Gynecol. 2013 Aug;122(2 Pt 2):449-52. doi: 10.1097/AOG.0b013e31829ce0f1.

PMID:
23884256
15.

Incidence of port site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patients.

Boone JD, Fauci JM, Barr ES, Estes JM, Bevis KS.

Gynecol Oncol. 2013 Oct;131(1):123-6. doi: 10.1016/j.ygyno.2013.06.041. Epub 2013 Jul 9.

PMID:
23845692
16.

The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy.

Boone JD, Fauci JM, Walters CL, Whitworth JM, Bevis KS, Alvarez RD.

Int J Gynecol Cancer. 2013 Feb;23(2):367-71. doi: 10.1097/IGC.0b013e318276d9da.

PMID:
23266649
17.

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN.

Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2.

18.

Morbidity and mortality conference in obstetrics and gynecology: a tool for addressing the 6 core competencies.

Bevis KS, Straughn JM Jr, Kendrick JE, Walsh-Covarrubias J, Kilgore LC.

J Grad Med Educ. 2011 Mar;3(1):100-3. doi: 10.4300/JGME-D-10-00093.1.

19.

Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

20.

Cervical conization and the risk of preterm delivery.

Bevis KS, Biggio JR.

Am J Obstet Gynecol. 2011 Jul;205(1):19-27. doi: 10.1016/j.ajog.2011.01.003. Epub 2011 Feb 23. Review.

PMID:
21345402
21.

Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.

Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2011 Apr;121(1):193-9. doi: 10.1016/j.ygyno.2010.11.046. Epub 2011 Jan 5.

PMID:
21211830
22.

Overcoming TRAIL resistance in ovarian carcinoma.

Bevis KS, Buchsbaum DJ, Straughn JM Jr.

Gynecol Oncol. 2010 Oct;119(1):157-63. doi: 10.1016/j.ygyno.2010.05.034. Epub 2010 Jul 16.

PMID:
20638107

Supplemental Content

Loading ...
Support Center